PMID- 23663006
OWN - NLM
STAT- MEDLINE
DCOM- 20140204
LR  - 20211203
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 22
IP  - 8
DP  - 2013 Aug
TI  - The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart 
      failure.
PG  - 1041-7
LID - 10.1517/13543784.2013.797963 [doi]
AB  - INTRODUCTION: Heart failure remains a syndrome with a very high mortality rate 
      and a poor quality of life. For patients with heart failure and a preserved 
      ejection fraction (HFpEF), no drugs have shown to improve mortality and 
      morbidity, and therefore novel drugs are highly needed. LCZ696 , a first in class 
      angiotensin receptor neprilysin inhibitor (ARNi), might be an interesting novel 
      drug for the treatment of heart failure. AREAS COVERED: Previous studies have 
      shown promising effects of a combination drug with a neutral endopeptidase and an 
      angiotensin-converting enzyme inhibitor (omapatrilat) for the treatment of 
      patients with heart failure. However, the occurrence of angioedema prevented the 
      drug from further development. The majority of this paper will discuss the 
      metabolism, pharmacokinetics, pharmacodynamics, clinical effects, and safety of 
      LCZ696, with a particular focus on heart failure. EXPERT OPINION: LCZ696 is 
      superior to valsartan alone in reducing blood pressure. Preliminary results from 
      a Phase II trial showed that LCZ696 reduced NT-proBNP to a greater extent than 
      valsartan alone, and in addition LCZ696 had beneficial effects on symptoms. With 
      these promising first results, the results of ongoing further studies in heart 
      failure are eagerly awaited.
FAU - Voors, Adriaan A
AU  - Voors AA
AD  - Professor of Cardiology, University of Groningen, University Medical Center 
      Groningen, Department of Cardiology, Groningen, The Netherlands. 
      a.a.voors@umcg.nl
FAU - Dorhout, Bernard
AU  - Dorhout B
FAU - van der Meer, Peter
AU  - van der Meer P
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130510
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - HG18B9YRS7 (Valine)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Aminobutyrates/*administration & dosage/adverse effects/pharmacokinetics
MH  - Angiotensin Receptor Antagonists/*administration & dosage/adverse 
      effects/pharmacokinetics
MH  - Animals
MH  - Biphenyl Compounds
MH  - Drug Combinations
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Neprilysin/antagonists & inhibitors
MH  - Tetrazoles/*administration & dosage/adverse effects/pharmacokinetics
MH  - Treatment Outcome
MH  - Valine/administration & dosage/*analogs & derivatives
MH  - Valsartan
EDAT- 2013/05/15 06:00
MHDA- 2014/02/05 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/05/14 06:00 [entrez]
PHST- 2013/05/15 06:00 [pubmed]
PHST- 2014/02/05 06:00 [medline]
AID - 10.1517/13543784.2013.797963 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2013 Aug;22(8):1041-7. doi: 
      10.1517/13543784.2013.797963. Epub 2013 May 10.